A PSEN2 genetic test during an Alzheimer's workup checks for inherited mutations that cause early-onset Alzheimer's disease. It is highly specific but not a rule-out test, needs a blood or saliva sample, and guides family next steps. PSEN2 is a gene that carries instructions for presenilin 2, part of an enzyme complex that cuts amyloid precursor protein into amyloid-beta peptide.
According to the U.S. National Library of Medicine, disease mutations disrupt this cutting process and cause overproduction of amyloid-beta MedlinePlus PSEN2 page. The same source notes at least 11 such mutations, which account for less than 5% of early-onset cases.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who is most likely to need this test?
- How far does a result go?
- How do you prepare?
- What happens after a positive result?
Who is most likely to need this test?
The American College of Medical Genetics and the National Society of Genetic Counselors report about 95% penetrance and typical symptom onset at ages 40-75 joint testing guidelines. Penetrance means the share of carriers who develop symptoms. APP and PSEN1 mutations show complete penetrance by comparison.
The same guidelines direct doctors to test the affected family member first. That result identifies the family's exact mutation before relatives consider predictive testing. Testing an unaffected person first can leave the family without a clear answer.
How far does a result go?
A 2013 Continuum review on early-onset testing stresses one limit. A negative PSEN1, PSEN2, and APP result does not rule out Alzheimer's disease. Unknown mutations exist, and false negatives occur.
A positive result also has a narrow meaning. It confirms a genetic cause only in a person who already shows symptoms. It does not replace the clinical workup that established the diagnosis.
How do you prepare?
Preparation is simple physically but deserves planning. A payer summary of the Fulgent Parkinson-Alzheimer-Dementia panel notes samples go to a clinical lab for sequencing, with results in about 3-5 weeks depending on the panel payer summary of the Fulgent panel.
The National Institute on Aging and the Alzheimer's Association recommend genetic counseling before and after testing. Results are hard to interpret and can cause emotional distress without offering prevention or cure. Counseling helps families weigh timing, privacy, and family communication.
- give a blood sample, or saliva or cheek swab for some panels
- confirm which genes the panel covers
- ask how results will arrive and who will explain them
What happens after a positive result?
Neurology follow-up comes first to guide care and monitoring. Families then discuss cascade testing, which offers at-risk relatives a chance to learn whether they carry the same mutation. Clear records of the exact mutation help relatives and counselors act.
Registries can add options for research and support. The National Institute on Aging points families to registries such as the Dominantly Inherited Alzheimer Network. The National Institute on Aging notes that the Dominantly Inherited Alzheimer Network offers counseling to participants Dominantly Inherited Alzheimer Network study page.
